Research Activity – Page 82

Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions

2 years ago talkbio0Tagged Artificial Intelligence, Biotechnology, Drug Discovery, genAI protein design, healthcare innovation, Nabla Bio, pharmaceutical partners, Protein Engineering

Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.

Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi

2 years ago talkbio0Tagged Alzheimer 's disease, Amyloid beta-Peptides, Biogen, Blackfoot language, Clinical Trials, Eisai, Leqembi, Monoclonal Antibodies, rolling, subcutaneous, Submission, United States Food and Drug Administration

Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder

Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study

2 years ago talkbio0Tagged Administration occupational activities, Benefit, Cardiovascular system, Clinical Research, Diabetes, Glucagon-Like Peptide-1 Receptor, heart health, Obesity, Wegovy

Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.

Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design

2 years ago talkbio0Tagged Artificial Intelligence, Biotechnology, Drug Discovery, generative, Nabla Bio, pharmaceutical partners, protein design

Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

2 years ago talkbio0Tagged 4-year, Approved, blockbuster drug, Clinical Trials, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.

Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS

2 years ago talkbio0Tagged BMS, Cardiomyopathies, Cardiovascular Diseases, Clinical Data, Cytokinetics, Heart failure, mecarbil, Myocardium, myosin inhibitors, omecamtiv, Phase 3 Clinical Trials

Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.

Lilly-backed Lycia Therapeutics Secures $106M for Clinical Trials on Lysosomal Protein Degraders

2 years ago talkbio0Tagged Biotechnology, Clinical Trials, Drug Development, Eli, Eli Lilly, Lycia Therapeutics, lysosomal protein

Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development

Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies

2 years ago talkbio0Tagged ASGCT24, Clinical Trials, Creyon, Freeline, gene therapy, Hemophilia A, Hereditary Diseases, Liver diseases, Parkinson 's disease, Rocket

ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.